Larazotide Research Handling Protocol — Research Reference
Larazotide (AT-1001) serves as a critical research tool for scientists investigating the intricate mechanisms of intestinal barrier function through its tight-junction regulating properties. This protocol provides indispensable guidelines for its precise handling, optimal storage, and rigorous experimental preparation, all designed to uphold the highest standards of data integrity and reproducibility across diverse research applications. Adherence to these recommendations is paramount for obtaining reliable and interpretable results in preclinical and mechanistic studies.
As a tight-junction peptide, Larazotide’s mechanism of action involves modulating the integrity of epithelial tight junctions, making it invaluable in studies exploring conditions associated with barrier dysfunction. The compound has garnered significant attention within the scientific community, reflected by numerous indexed publications on PubMed and several registered studies on ClinicalTrials.gov, all contributing to a growing understanding of its potential as a research probe in various preclinical models. This document is strictly intended for research use only, guiding laboratory professionals in the proper and safe application of Larazotide in non-human experimental contexts.
Larazotide Compound Profile and Research Context
Larazotide, also known by its alias AT-1001, is a synthetic tight-junction-regulating peptide that has garnered significant attention within the scientific community for its potential utility in models pertaining to intestinal barrier function. Its classification as a tight-junction peptide underscores its mechanism of action, which involves modulation of the paracellular pathway, a critical component of epithelial integrity. This peptide is characterized by its specific amino acid sequence, which is designed to interact with and influence the intricate protein complexes forming tight junctions between cells. Research into Larazotide primarily focuses on understanding its impact on barrier permeability and its potential to mitigate conditions where barrier disruption plays a pathophysiological role. The extensive body of work surrounding Larazotide highlights its relevance as a research tool for investigating epithelial barrier dynamics in various experimental settings.
The research landscape for Larazotide is robust, with numerous publications indexed in PubMed detailing its investigation across a spectrum of preclinical studies. These studies span various scientific disciplines, including gastroenterology, immunology, and pharmacology, consistently contributing to the understanding of tight junction regulation. Furthermore, Larazotide has been the subject of several registered studies on ClinicalTrials.gov, indicating its progression into human-focused investigation, primarily for understanding its pharmacological properties and potential biological effects, rather than for therapeutic claims. For researchers utilizing Larazotide, an understanding of its established role in tight-junction research is paramount, providing a foundational context for designing new experiments and interpreting results within the broader scientific narrative. Further information on the general research trajectory of this compound can be explored at Larazotide Research Overview.
As a research tool, Larazotide offers investigators a defined agent to perturb or stabilize tight junctions in controlled experimental conditions. Its utility extends to mechanistic studies aimed at elucidating the molecular pathways involved in barrier regulation, as well as translational studies exploring the impact of barrier dysfunction in various disease models. The peptide’s consistent presence in peer-reviewed literature and clinical study registries suggests a well-characterized compound suitable for rigorous scientific inquiry. Researchers are encouraged to review the existing literature to inform their experimental designs, ensuring that their work builds upon established knowledge while contributing novel insights into tight junction biology and its implications for health and disease. Comprehensive understanding of its action can be found at Larazotide Mechanism of Action.
Purity, Identity, and Characterization for Research Use
For any research peptide, especially one with a specific mechanism of action like Larazotide, the assurance of high purity and confirmed identity is absolutely critical for obtaining reliable and reproducible experimental results. Impurities, even in trace amounts, can introduce variability, lead to off-target effects, or confound experimental outcomes, rendering research data inconclusive or erroneous. At Royal Peptide Labs, rigorous analytical methods are employed to ensure that Larazotide supplied for research purposes meets stringent quality specifications. These methods are designed to unequivocally confirm the peptide’s chemical structure, assess its purity profile, and quantify its peptide content, providing researchers with the confidence necessary for their studies. A thorough understanding of peptide quality assurance is essential for any discerning researcher, which is further detailed on our Quality Testing page.
Comprehensive Analytical Characterization
The characterization of Larazotide involves a multi-faceted approach utilizing a suite of advanced analytical techniques. High-Performance Liquid Chromatography (HPLC) is routinely employed to determine the peptide’s purity, typically aiming for >98% purity, and to identify any related impurities or degradation products. The chromatographic profile provides a quantitative assessment of the main peptide component relative to any co-eluting species. Mass Spectrometry (MS), particularly Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS), is used to confirm the exact molecular weight of the peptide, which directly correlates with its amino acid sequence and structure. Deviations in observed mass from the theoretical mass can indicate incorrect synthesis, post-translational modifications, or unintended adducts, all of which would compromise the peptide’s identity and suitability for research.
Peptide Content and Counter-Ion Analysis
Beyond purity and molecular weight, accurate determination of peptide content is vital for precise dosing in research experiments. Peptides are often supplied as salts (e.g., trifluoroacetate, acetate) and may contain residual moisture. Amino Acid Analysis (AAA) provides a direct measure of the molar ratio of constituent amino acids, thereby allowing for the calculation of the precise peptide content after accounting for non-peptide components. This ensures that researchers are accurately weighing and reconstituting the active peptide component. Furthermore, counter-ion analysis, often performed via ion chromatography, quantifies the amount of residual counter-ion present. The type and amount of counter-ion can influence solubility, stability, and even biological activity, making its characterization an important aspect of a comprehensive quality assessment. Researchers should always refer to the specific peptide content when calculating dilutions, not just the gross weight of the lyophilized material.
Certificate of Analysis (CoA) for Transparency
Each batch of Larazotide supplied for research comes with a comprehensive Certificate of Analysis (CoA). This document serves as a transparent declaration of the peptide’s quality, detailing the results of the aforementioned analytical tests. A typical CoA for Larazotide will include: the lot number, peptide name and alias, sequence, molecular weight, gross weight, peptide content (typically as a percentage), purity by HPLC, confirmation of molecular weight by MS, and typically a statement regarding residual counter-ion. Researchers should meticulously review the CoA provided with their material, as it contains critical information for experimental design, particularly concerning accurate concentration preparation and interpretation of results. Access to the CoA for your specific batch can be found via the Certificate of Analysis portal, ensuring full traceability and confidence in the material’s quality.
Safe Handling and Laboratory Best Practices for Peptides
Adhering to strict safety protocols and laboratory best practices is paramount when handling any research chemical, including peptides like Larazotide. While peptides are generally considered less acutely toxic than some other classes of laboratory reagents, their biological activity, potential for sensitization, and unknown long-term effects necessitate careful handling. As Larazotide is intended strictly for research use, its safety profile in humans, particularly with chronic exposure or in high doses, has not been fully established. Therefore, all handling procedures must assume potential hazards and employ appropriate precautions to minimize exposure to laboratory personnel and prevent environmental contamination. This diligent approach ensures both researcher safety and the integrity of experimental work.
Personal Protective Equipment (PPE)
The foundational element of safe laboratory practice is the consistent use of appropriate personal protective equipment (PPE). When handling Larazotide, whether in its lyophilized powder form or as a solution, the following PPE should be considered minimum requirements:
- Laboratory Coat: A clean, properly fitted lab coat should be worn to protect personal clothing and skin from potential splashes or spills.
- Safety Glasses or Goggles: Eye protection is essential to prevent chemical contact with the eyes, especially during weighing or solution preparation.
- Nitrile Gloves: Disposable nitrile gloves should be worn to prevent skin contact. Gloves should be changed regularly, especially after contact with the peptide or when moving between different work areas, to avoid cross-contamination. Double gloving may be considered for increased protection when handling concentrated stock solutions or large quantities of powder.
- Respiratory Protection (for powders): When handling lyophilized powder, particularly during weighing or transfer, there is a risk of aerosolization. Working within a certified chemical fume hood or, if aerosolization risk is high, using appropriate respiratory protection (e.g., N95 respirator) is recommended to prevent inhalation.
Always consult institutional safety guidelines and conduct a thorough risk assessment for each specific procedure involving Larazotide.
Laboratory Environment and Spill Management
All manipulations involving Larazotide, particularly the weighing and reconstitution of lyophilized powder, should be performed in a designated area, ideally within a certified chemical fume hood or a biological safety cabinet if sterility is also a concern. This provides containment and minimizes the risk of inhalation and environmental contamination. Work surfaces should be protected with absorbent bench paper to contain any spills. In the event of a spill, immediately don appropriate PPE, if not already wearing it, and clean the affected area thoroughly using an appropriate decontaminant (e.g., 70% ethanol or a mild detergent solution) followed by water. All contaminated materials, including gloves, paper towels, and pipette tips, must be collected and disposed of as chemical waste in accordance with local regulations. Never pour peptide solutions down the drain; always collect and dispose of them as hazardous waste.
Preventing Cross-Contamination and Waste Disposal
To maintain the integrity of research and prevent unintended exposure, meticulous practices regarding cross-contamination are critical. Use dedicated equipment (spatulas, glassware, pipettes) for Larazotide or ensure thorough cleaning between uses. Store Larazotide in clearly labeled containers, separate from other reagents, and ensure proper sealing to prevent leakage or degradation. All waste materials, including spent solutions, contaminated consumables, and empty containers, must be segregated and disposed of as chemical hazardous waste. Consult your institution’s Environmental Health and Safety (EHS) department for specific guidelines on hazardous waste classification and disposal procedures for peptides. Under no circumstances should Larazotide or its solutions be released into the environment or disposed of as general waste, underscoring its strict research-use-only designation.
Larazotide Storage and Stability Considerations
The long-term stability and integrity of Larazotide are paramount for reproducible research outcomes. Peptides, by their nature, are susceptible to degradation through various pathways, including hydrolysis, oxidation, and enzymatic cleavage. Proper storage conditions are therefore essential to maintain the purity, potency, and structural integrity of Larazotide from the point of receipt through the duration of its experimental use. Deviations from recommended storage protocols can lead to peptide degradation, altered activity, and consequently, unreliable experimental data. It is crucial for researchers to meticulously adhere to these guidelines to ensure the consistent quality of their research material.
Storage of Lyophilized Larazotide Powder
Larazotide is typically supplied as a lyophilized (freeze-dried) powder to maximize its long-term stability. The recommended storage conditions for the lyophilized form are:
- Temperature: Long-term storage should be at -20°C or colder (e.g., -80°C for extended periods). Freezing significantly slows down chemical degradation processes.
- Desiccation: The peptide should be stored in a tightly sealed container, ideally with a desiccant, to prevent moisture absorption. Moisture is a primary catalyst for hydrolysis and can dramatically reduce the peptide’s shelf life.
- Light Protection: Store in the dark or in amber vials/containers to protect from light exposure. While not all peptides are photosensitive, protecting them from UV and visible light is a good general practice to prevent photo-oxidation.
- Minimizing Freeze-Thaw Cycles: While lyophilized, freeze-thaw cycles are generally less detrimental than for solutions, it is still best practice to minimize opening the container and exposing the peptide to ambient conditions. Aliquoting the powder into smaller, single-use portions, if practical, can further extend its overall shelf life by reducing exposure.
Following these guidelines will preserve the quality of the Larazotide powder for the duration specified on its Certificate of Analysis.
Stability of Larazotide Solutions
Once reconstituted, Larazotide solutions become significantly more susceptible to degradation. The stability of a peptide in solution is influenced by several factors, including the solvent system, pH, concentration, temperature, and presence of proteases or microbial contamination. For stock solutions:
- Solvent Choice: The initial reconstitution solvent should be chosen carefully. While water or a mild aqueous buffer (e.g., PBS) may be suitable for short-term use, solvents like dilute acetic acid (0.1% v/v) can sometimes enhance stability for peptides prone to aggregation or basic pH-induced degradation. DMSO or other organic co-solvents can improve solubility for hydrophobic peptides, but their long-term stability implications must be considered.
- Temperature: Stock solutions should be stored at -20°C or -80°C. Storage at 4°C is generally acceptable for short periods (e.g., 1-2 weeks), but not for long-term preservation.
- Freeze-Thaw Cycles: Repeated freeze-thaw cycles are highly detrimental to peptide integrity in solution. They can lead to aggregation, precipitation, and increased degradation. It is strongly recommended to prepare single-use aliquots of stock solutions and freeze them. Thaw only the aliquot needed for an experiment, and discard any unused portion rather than refreezing.
- pH and Proteases: Extreme pH values (both highly acidic and highly alkaline) can accelerate hydrolysis. Buffers should be chosen to maintain a physiological or near-physiological pH, unless specific experimental conditions dictate otherwise. The presence of proteases in serum-containing media or biological samples can rapidly degrade peptides; consider using protease inhibitors if working with such matrices.
- Microbial Contamination: Always prepare solutions under sterile conditions using sterile solvents and glassware to prevent microbial growth, which can lead to rapid peptide degradation. Filter sterilization (e.g., 0.22 µm syringe filter) of aqueous solutions before freezing is also recommended.
Consult the specific handling and storage recommendations provided on the Larazotide Storage and Handling page for the most up-to-date and detailed guidance, as recommendations may be refined based on ongoing stability studies.
Preparation of Larazotide Solutions for Experimental Applications
Accurate and sterile preparation of Larazotide solutions is a critical step that directly impacts the reliability and reproducibility of experimental results. Improper reconstitution or dilution can lead to inaccurate dosing, peptide degradation, aggregation, or contamination, thereby compromising the scientific validity of the research. This section outlines the best practices for preparing Larazotide solutions, from reconstituting the lyophilized powder to creating working dilutions for various experimental applications, with an emphasis on precision and aseptic technique.
Reconstitution of Lyophilized Larazotide Powder
The first step involves reconstituting the lyophilized Larazotide powder into a concentrated stock solution. The choice of solvent and the method of dissolution are crucial. For Larazotide, an aqueous solution is generally preferred due to its inherent hydrophilicity as a peptide. High-quality, sterile, deionized water (e.g., HPLC-grade water for non-biological assays or sterile water for cell culture) is often the initial solvent of choice. If solubility is an issue, a small amount of a co-solvent such as dimethyl sulfoxide (DMSO) or acetonitrile may be used, though careful consideration must be given to the potential effects of these solvents on the experimental system. For instance, DMSO concentrations typically should not exceed 0.1-1.0% (v/v) in cell culture. Alternatively, dilute aqueous acids (e.g., 0.1% acetic acid) or bases (e.g., 10 mM ammonium bicarbonate) can sometimes aid dissolution for peptides that are less soluble in neutral water, depending on their isoelectric point.
To reconstitute, carefully warm the vial of lyophilized Larazotide to room temperature before opening to minimize condensation. Add the calculated volume of the chosen solvent directly to the powder, ensuring the solvent stream washes down any peptide adhering to the vial walls. Avoid vigorous shaking, which can induce aggregation or denaturation; instead, gently swirl or pipette up and down to dissolve the peptide. If necessary, allow the vial to sit at room temperature for a short period (e.g., 10-20 minutes) to facilitate complete dissolution. Gentle sonication in a water bath can be employed as a last resort for recalcitrant powders, but only for brief periods and with caution to avoid peptide damage. Once dissolved, the solution should appear clear and free of particulate matter. Calculate the exact amount of peptide to be weighed based on the peptide content specified on the Certificate of Analysis (CoA), not just the gross weight of the lyophilized material. For example, if a vial contains 5 mg of gross material with 80% peptide content, the actual peptide amount is 4 mg. To make a 1 mM solution of a peptide with a molecular weight of 1000 Da (1 mg/µmol), you would need 1 mg of peptide in 1 mL of solvent. Thus, for 4 mg of actual peptide, you would add 4 mL of solvent to achieve a 1 mM stock.
Preparation of Stock and Working Solutions
Once the primary stock solution is prepared, it is highly recommended to create single-use aliquots. This minimizes the detrimental effects of repeated freeze-thaw cycles and reduces the risk of contamination over time. Aliquot the stock solution into sterile microcentrifuge tubes or cryogenic vials, ensuring each aliquot contains enough volume for one or a few experiments. Label each aliquot clearly with the peptide name, concentration, solvent, date of preparation, and lot number. Freeze aliquots immediately at -20°C or -80°C. When an aliquot is needed for an experiment, thaw it completely on ice, use it, and discard any remaining portion. Never refreeze thawed aliquots.
For experimental applications, working solutions are prepared by diluting the stock solution to the desired concentration using the appropriate cell culture media, buffer, or vehicle. This dilution should be performed aseptically if the solution is intended for *in vitro* or *in vivo* applications. Filter sterilization through a 0.22 µm syringe filter is strongly recommended for all solutions intended for cell culture or animal administration to remove any potential microbial contaminants. Ensure the chosen filter material is compatible with the peptide and solvent to avoid adsorption or leaching. Always prepare working solutions fresh for each experiment to ensure maximum peptide integrity and activity.
Considerations for *In Vitro* Research Models
The successful application of Larazotide in *in vitro* research models requires meticulous attention to experimental design and execution to ensure accurate and interpretable results. *In vitro* systems, ranging from two-dimensional cell monolayers to complex organ-on-a-chip platforms, offer controlled environments for studying cellular responses to Larazotide’s tight-junction-regulating activity. However, researchers must account for several critical factors that can influence peptide stability, bioavailability, and biological effect within these model systems, thereby impacting the validity of their findings.
Cell Culture Systems and Media Compatibility
Selecting the appropriate cell culture model is paramount. Given Larazotide’s mechanism of action, epithelial cell lines (e.g., Caco-2, T84, MDCK) that form functional tight junctions are often utilized. Researchers should ensure that the chosen cell line authentically represents the barrier biology under investigation. Once the cell line is selected, media compatibility becomes a key consideration. Standard cell culture media contain various components, including amino acids, salts, vitamins, and potentially serum. The presence of serum, while supporting cell growth, introduces proteases that can degrade peptides. Therefore, experiments involving Larazotide might benefit from serum-free conditions, reduced serum concentrations, or the inclusion of protease inhibitors, particularly during the peptide incubation period. The pH and osmolarity of the culture medium should also be maintained within physiological ranges, as extreme conditions can affect both peptide stability and cellular tight junction integrity independently of Larazotide’s action. All solutions containing Larazotide intended for cell culture should be filter-sterilized (0.22 µm) to prevent microbial contamination.
Dose-Response and Incubation Parameters
Establishing an appropriate dose-response curve for Larazotide is fundamental for *in vitro* studies. Researchers should conduct preliminary experiments to determine the effective concentration range, typically starting with a broad range and narrowing it down. Concentrations should be based on the actual peptide content, as specified in the Certificate of Analysis, not the gross weight of the lyophilized material. The duration of Larazotide exposure is equally important; tight junction modulation is a dynamic process, and optimal incubation times may vary depending on the cell type, the specific assay, and the desired effect (e.g., acute barrier opening versus long-term stabilization). Repeated measurements over a time course may be necessary to capture the full kinetic profile of Larazotide’s action. Controls, including untreated cells and vehicle-treated cells, are indispensable for distinguishing peptide-specific effects from general cellular responses or solvent effects.
Assays for Tight Junction Integrity and Off-Target Effects
To assess Larazotide’s impact on tight junctions, various quantitative assays can be employed. Trans-Epithelial Electrical Resistance (TEER) is a widely used, non-invasive method to monitor the integrity of cell monolayers, providing a real-time measure of barrier function. A decrease in TEER typically indicates increased paracellular permeability, while an increase suggests enhanced barrier integrity. Paracellular flux assays, using inert macromolecules like fluorescein isothiocyanate (FITC)-dextran of various molecular weights, directly quantify the passage of substances across the cell monolayer, offering a complementary measure of barrier permeability
Frequently Asked Questions
What is Larazotide’s primary mechanism of action in research?
Larazotide, also known as AT-1001, functions as a tight-junction regulating peptide. Its primary research utility stems from its ability to modulate the integrity of epithelial tight junctions, making it a valuable tool for investigating intestinal barrier function and its role in various research models of barrier dysfunction.
How should Larazotide be stored for long-term research stability?
For optimal long-term stability in research settings, Larazotide, typically supplied as a lyophilized powder, should be stored at -20°C or colder (e.g., -80°C). It is crucial to keep the compound protected from light and moisture, often in a desiccated environment, to prevent degradation and maintain its research-grade purity.
What purity level is generally recommended for Larazotide in research?
For most rigorous research applications, Larazotide with a purity of ≥95% by High-Performance Liquid Chromatography (HPLC) is typically recommended. For highly sensitive or critical mechanistic studies, an even higher purity, often ≥98%, alongside comprehensive characterization using techniques like Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR), is advisable to ensure experimental consistency and data reliability.
What are common diluents for preparing Larazotide research solutions?
Common diluents for preparing Larazotide research solutions include sterile deionized water, phosphate-buffered saline (PBS) at physiological pH, or other specific biocompatible buffers. The choice of diluent should always be dictated by the specific experimental application, considering factors such as pH, osmolality, and compatibility with the target biological system.
Can Larazotide be re-lyophilized after reconstitution?
While technically possible under specific, carefully controlled conditions, re-lyophilization of Larazotide after initial reconstitution is generally not recommended for research applications. This process can potentially lead to peptide degradation, aggregation, or loss of activity due to exposure to freeze-thaw cycles or incomplete drying, thereby compromising the integrity of subsequent research. For optimal results, reconstituted solutions should be used promptly or aliquoted and stored as per stability guidelines, avoiding repeated freeze-thaw cycles.
What are the key safety precautions when handling Larazotide in the lab?
When handling Larazotide in the laboratory, researchers must adhere to standard chemical hygiene practices and employ appropriate personal protective equipment (PPE). This includes wearing laboratory coats, safety glasses, and chemical-resistant gloves. When handling the lyophilized powder, working within a certified fume hood is recommended to minimize potential inhalation of aerosols. Avoid direct skin contact, ingestion, and inhalation, and always consult the compound’s Safety Data Sheet (SDS) for specific hazard information.
How is Larazotide typically characterized to confirm its identity for research?
Confirmation of Larazotide’s identity for research typically involves a combination of analytical techniques. Mass Spectrometry (MS), particularly Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF, is used to verify the molecular weight. High-Performance Liquid Chromatography (HPLC) provides purity assessment and confirms retention time. In some cases, Nuclear Magnetic Resonance (NMR) spectroscopy can be employed for detailed structural elucidation, and amino acid analysis may be used to confirm its constituent amino acids.
What kind of research models typically utilize Larazotide?
Larazotide is predominantly utilized in research models focused on epithelial barrier function, particularly those related to the intestinal barrier. This includes *in vitro* cell culture models, such as Caco-2 cell monolayers or other intestinal epithelial cell lines, where its effects on Transepithelial Electrical Resistance (TEER) and paracellular flux can be investigated. It is also extensively used in *in vivo* animal models, including rodents, to study its impact on intestinal permeability in the context of various induced conditions like inflammatory bowel disease (IBD) or chemically induced colitis models.
Scientific References
All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.